Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Integrative Perspectives on Pirfenidone: Mechanistic Insights, Pharmacodynamics, and Emerging Therapeutic Strategies for Fibrotic Disorders.AAPS PharmSciTech · 2026
   Review
2. Emerging Therapies in Pulmonary Fibrosis.Pulmonary therapy · 2026
   Review
3. Optimizing patient outcomes in interstitial lung disease through pre- and post-transplant management strategies.World journal of transplantation · 2025
   Review
4. Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis.Frontiers in pharmacology · 2020
   Article
5. Investigating the effects of Pirfenidone on TGF-β1 stimulated non-SMAD signaling pathways in Dupuytren's disease -derived fibroblasts.BMC musculoskeletal disorders · 2019
   Article

Corrections and comments

• Erratum issued
  Correction to: Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract